A. Pereslete

Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast Cancer

N. Lin, B. Overmoyer, M. Hughes, 2022, medRxiv.

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases

N. Lin, C. Lascola, Jean J. Zhao, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial

R. Barroso-Sousa, S. Tolaney, Jorge Gómez Tejeda Zañudo, 2024, Nature communications.